AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio r&d expenses
Research and development expenses are spending on new products and technology.
AnaptysBio's R&D Expenses for the twelve months ending Mar 31, 2026 was $128.78M, down 23.3% year over year. For fiscal 2025 it was $135.97M, down 17.0% from the year before. Over ten years it grew 22.9% a year on average. The highest annual figure on record is $163.84M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.97M | -17.0% |
| FY2024 | Dec 31, 2024 | $163.84M | +23.9% |
| FY2023 | Dec 31, 2023 | $132.28M | +49.0% |
| FY2022 | Dec 31, 2022 | $88.80M | -9.8% |
| FY2021 | Dec 31, 2021 | $98.50M | +23.1% |
| FY2020 | Dec 31, 2020 | $80.03M | -19.4% |
| FY2019 | Dec 31, 2019 | $99.34M | +76.8% |
| FY2018 | Dec 31, 2018 | $56.20M | +90.9% |
| FY2017 | Dec 31, 2017 | $29.44M | +91.0% |
| FY2016 | Dec 31, 2016 | $15.42M | -10.9% |
| FY2015 | Dec 31, 2015 | $17.30M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $33.99M | -17.5% |
| Q4 FY2025 | Dec 31, 2025 | $25.56M | -40.0% |
| Q3 FY2025 | Sep 30, 2025 | $31.41M | -25.6% |
| Q2 FY2025 | Jun 30, 2025 | $37.82M | -9.9% |
| Q1 FY2025 | Mar 31, 2025 | $41.18M | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $42.59M | +27.0% |
| Q3 FY2024 | Sep 30, 2024 | $42.21M | +36.7% |
| Q2 FY2024 | Jun 30, 2024 | $42.00M | +27.6% |
| Q1 FY2024 | Mar 31, 2024 | $37.04M | +6.0% |
| Q4 FY2023 | Dec 31, 2023 | $33.53M | +43.4% |
| Q3 FY2023 | Sep 30, 2023 | $30.88M | +39.9% |
| Q2 FY2023 | Jun 30, 2023 | $32.92M | +57.9% |
| Q1 FY2023 | Mar 31, 2023 | $34.96M | +55.3% |
| Q4 FY2022 | Dec 31, 2022 | $23.37M | -12.7% |
| Q3 FY2022 | Sep 30, 2022 | $22.06M | -0.7% |
| Q2 FY2022 | Jun 30, 2022 | $20.84M | -17.7% |
| Q1 FY2022 | Mar 31, 2022 | $22.52M | -6.9% |
| Q4 FY2021 | Dec 31, 2021 | $26.78M | +24.2% |
| Q3 FY2021 | Sep 30, 2021 | $22.22M | +13.7% |
| Q2 FY2021 | Jun 30, 2021 | $25.31M | +41.0% |
| Q1 FY2021 | Mar 31, 2021 | $24.19M | +15.3% |
| Q4 FY2020 | Dec 31, 2020 | $21.57M | +0.7% |
| Q3 FY2020 | Sep 30, 2020 | $19.54M | -34.7% |
| Q2 FY2020 | Jun 30, 2020 | $17.95M | -34.4% |
| Q1 FY2020 | Mar 31, 2020 | $20.97M | +1.6% |
| Q4 FY2019 | Dec 31, 2019 | $21.43M | +34.6% |
| Q3 FY2019 | Sep 30, 2019 | $29.93M | +67.4% |
| Q2 FY2019 | Jun 30, 2019 | $27.35M | +158.4% |
| Q1 FY2019 | Mar 31, 2019 | $20.63M | +74.7% |
| Q4 FY2018 | Dec 31, 2018 | $15.92M | +109.3% |
| Q3 FY2018 | Sep 30, 2018 | $17.88M | +167.0% |
| Q2 FY2018 | Jun 30, 2018 | $10.58M | +46.9% |
| Q1 FY2018 | Mar 31, 2018 | $11.81M | +48.8% |
| Q4 FY2017 | Dec 31, 2017 | $7.61M | +51.6% |
| Q3 FY2017 | Sep 30, 2017 | $6.70M | +104.1% |
| Q2 FY2017 | Jun 30, 2017 | $7.21M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.02M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.28M | – |
See a number that looks wrong?